GSK's 2014 revenues fall but shares climb on upbeat respiratory talk
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline shares closed 2% up as investors were pleasantly surprised by better than expected earnings for the fourth quarter of 2014. As anticipated, total revenue for the year dropped 3% to £23.0bn following "challenging trading conditions particularly in the US primary care market," said CEO Sir Andrew Witty.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.